TY - JOUR
T1 - Guidelines for the management of acute porphyria
T2 - recommendations from the International Porphyria Network
AU - Edel, Yonatan
AU - Stein, Penelope E.
AU - Kawtharany, Hassan
AU - Aarsand, Aasne K.
AU - Badminton, Michael
AU - Balwani, Manisha C.
AU - Bonkovsky, Herbert L.
AU - Cappellini, Maria Domenica
AU - Cassiman, David
AU - Deybach, Jean Charles
AU - Gill, Liz
AU - Harper, Pauline
AU - Hift, Richard
AU - Kauppinen, Raili
AU - Ivanova, Aneta
AU - Langendonk, Janneke
AU - Marcacci, Matteo
AU - Minder, Anna Elizabeth
AU - Naik, Hetanshi
AU - Pischik, Elena
AU - Petrides, Petro E.
AU - Rees, David
AU - Richie, Bruce
AU - Sardh, Eliane
AU - Schmitt, Caroline
AU - Schulenburg-Brand, Danja
AU - Sonderup, Mark
AU - Stölzel, Ulrich
AU - To-Figueras, Jordi
AU - Ventura, Paolo
AU - Wohmann, Nils
AU - Mustafa, Reem
AU - Sandberg, Sverre
N1 - Publisher Copyright:
© 2026 Elsevier Ltd.
PY - 2026/5
Y1 - 2026/5
N2 - Autosomal dominant acute porphyrias are rare inherited disorders of haem biosynthesis characterised by accumulation of potentially neurotoxic porphyrin precursors and attacks of severe abdominal pain with autonomic and neuropsychiatric features. Disease severity ranges from asymptomatic individuals to those with recurrent, life-threatening attacks. The International Porphyria Network invited 34 acute porphyria specialists from 17 countries to form an expert panel. The invited group included clinicians from diverse specialities (ie, internal medicine, haematology, endocrinology, gastroenterology, hepatology, neurology, and biochemistry), together with laboratory scientists and patient representatives. The panel met online (in 2023–25) to develop 15 evidence-based recommendations with the use of the Grading of Recommendations, Assessment, Development, and Evaluations framework addressing attack prevention, management of sporadic and recurrent attacks, long-term follow-up, surveillance for primary liver cancer, and family screening. The guidelines support safe, consistent clinical care and improved outcomes, recognising global variation in resources and access to high-cost drugs, and highlighting priorities for future research.
AB - Autosomal dominant acute porphyrias are rare inherited disorders of haem biosynthesis characterised by accumulation of potentially neurotoxic porphyrin precursors and attacks of severe abdominal pain with autonomic and neuropsychiatric features. Disease severity ranges from asymptomatic individuals to those with recurrent, life-threatening attacks. The International Porphyria Network invited 34 acute porphyria specialists from 17 countries to form an expert panel. The invited group included clinicians from diverse specialities (ie, internal medicine, haematology, endocrinology, gastroenterology, hepatology, neurology, and biochemistry), together with laboratory scientists and patient representatives. The panel met online (in 2023–25) to develop 15 evidence-based recommendations with the use of the Grading of Recommendations, Assessment, Development, and Evaluations framework addressing attack prevention, management of sporadic and recurrent attacks, long-term follow-up, surveillance for primary liver cancer, and family screening. The guidelines support safe, consistent clinical care and improved outcomes, recognising global variation in resources and access to high-cost drugs, and highlighting priorities for future research.
UR - https://www.scopus.com/pages/publications/105037587280
U2 - 10.1016/S2352-3026(26)00044-X
DO - 10.1016/S2352-3026(26)00044-X
M3 - Review article
C2 - 42069412
AN - SCOPUS:105037587280
SN - 2451-9960
VL - 13
SP - e338-e350
JO - The Lancet Haematology
JF - The Lancet Haematology
IS - 5
ER -